PPI-668: Phase Ia data

A double-blind, placebo-controlled, dose-ranging, New Zealand Phase Ia portion of a Phase I trial in 32 healthy volunteers showed 3 doses of oral PPI-668 were well-tolerated, and the pharmacokinetic p...